Metformin in 2019.
Flory J, Lipska K.
JAMA. 2019 May 21;321(19):1926-1927. doi: 10.1001/jama.2019.3805.
Metformin in patients with type 2 diabetes and kidney disease: a systematic review.
Inzucchi SE, Lipska KJ, Mayo H, Bailey CJ, McGuire DK.
JAMA. 2014 Dec 24-31;312(24):2668-75. doi: 10.1001/jama.2014.15298.
Metformin-associated lactic acidosis: Current perspectives on causes and risk.
DeFronzo R, Fleming GA, Chen K, Bicsak TA.
Metabolism. 2016 Feb;65(2):20-9. doi: 10.1016/j.metabol.2015.10.014. Epub 2015 Oct 9.
Metformin: historical overview.
Bailey CJ.
Diabetologia. 2017 Sep;60(9):1566-1576. doi: 10.1007/s00125-017-4318-z. Epub 2017 Aug 3.
Clinical pharmacokinetics of metformin.
Scheen AJ.
Clin Pharmacokinet. 1996 May;30(5):359-71. doi: 10.2165/00003088-199630050-00003.
Metformin-associated lactic acidosis.
Fadden EJ, Longley C, Mahambrey T.
BMJ Case Rep. 2021 Jul 8;14(7):e239154. doi: 10.1136/bcr-2020-239154.
Metformin: When Should We Fear Lactic Acidosis?
Di Mauro S, Filippello A, Scamporrino A, Purrello F, Piro S, Malaguarnera R.
Int J Mol Sci. 2022 Jul 28;23(15):8320. doi: 10.3390/ijms23158320.
A review of phenformin, metformin, and imeglimin.
Yendapally R, Sikazwe D, Kim SS, Ramsinghani S, Fraser-Spears R, Witte AP, La-Viola B.
Drug Dev Res. 2020 Jun;81(4):390-401. doi: 10.1002/ddr.21636. Epub 2020 Jan 9.
Metformin: Past, Present, and Future.
Chaudhary S, Kulkarni A.
Curr Diab Rep. 2024 Jun;24(6):119-130. doi: 10.1007/s11892-024-01539-1. Epub 2024 Apr 3.
Lactic acidosis incidence with metformin in patients with type 2 diabetes and chronic kidney disease: A retrospective nested case-control study.
Alvarez CA, Halm EA, Pugh MJV, McGuire DK, Hennessy S, Miller RT, Lingvay I, Vouri SM, Zullo AR, Yang H, Chansard M, Mortensen EM.
Endocrinol Diabetes Metab. 2020 Jul 17;4(1):e00170. doi: 10.1002/edm2.170. eCollection 2021 Jan.
